Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

Trial Profile

A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2018 Planned End Date changed from 27 Dec 2018 to 7 Sep 2018.
    • 20 Jul 2018 Planned primary completion date changed from 27 Dec 2018 to 7 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top